SCHEMBL5734287

SCHEMBL5734287

COC(=O)C=C1SC(Nc2c(Cl)cccc2Cl)=NC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MAPT P10636 6/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ PLA2G1B P04054 1/20 0.39
▸ ATG4B Q9Y4P1 1/20 0.39
▸ CISD1 Q9NZ45 1/20 0.37
▸ HTT P42858 2/20 0.36
▸ RECQL P46063 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ ALOX5 P09917 2/20 0.36
▸ HPGD P15428 2/20 0.35
▸ ALOX12 P18054 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ HDAC3 O15379 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5734285 1.00 ALDH1A1 (0.39) ALDH1A1KMT2ARAB9AMAPTMEN1
SCHEMBL5737082 0.88 LCK (0.38) ALDH1A1KMT2ARAB9AMAPTCISD1
SCHEMBL5737084 0.88 LCK (0.38) ALDH1A1KMT2ARAB9AMAPTCISD1
SCHEMBL5736379 0.88 MAPT (0.46) ALDH1A1KMT2ARAB9AMAPTMEN1
SCHEMBL5736377 0.88 MAPT (0.46) ALDH1A1KMT2ARAB9AMAPTMEN1
SCHEMBL5734052 0.87 KDM4E (0.40) ALDH1A1KMT2ARAB9AMAPTMEN1
SCHEMBL5734055 0.87 KDM4E (0.40) ALDH1A1KMT2ARAB9AMAPTMEN1
SCHEMBL5735213 0.86 CISD1 (0.35) ALDH1A1KMT2AMAPTMEN1CISD1
SCHEMBL5737264 0.86 RAB9A (0.41) ALDH1A1KMT2ARAB9AMAPTMEN1
SCHEMBL5737261 0.86 RAB9A (0.41) ALDH1A1KMT2ARAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1314426-B1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER LAMBERT CO (US) 2006-02-15 — — EP claimed
US-6632831-B2 Such as: (2-(2,6-Dichloro-phenylamino)-4-oxo-4H-thiazol-5-ylidene)-acet ic acid methyl ester PFIZER INC. 2003-10-14 — — US claimed
EP-1314426-A9 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY (US) 2003-09-17 — — EP claimed
US-20030162779-A1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY 2003-08-28 — — US claimed
WO-2003045384-A1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY LLC (US) 2003-06-05 — — WO claimed
EP-1314426-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY (US) 2003-05-28 — — EP claimed
EP-1314426-B1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER LAMBERT CO (US) 2006-02-15 — — EP disclosed
WO-2004034288-A1 THE THREE-DIMENSIONAL CRYSTAL STRUCTURE OF BCATC COMPLEXES AND METHODS OF USE THEREOF WARNER-LAMBERT COMPANY LLC (US) 2004-04-22 — — WO disclosed
US-6632831-B2 Such as: (2-(2,6-Dichloro-phenylamino)-4-oxo-4H-thiazol-5-ylidene)-acet ic acid methyl ester PFIZER INC. 2003-10-14 — — US disclosed
EP-1314426-A9 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY (US) 2003-09-17 — — EP disclosed
US-20030162779-A1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY 2003-08-28 — — US disclosed
WO-2003045384-A1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY LLC (US) 2003-06-05 — — WO disclosed
EP-1314426-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY (US) 2003-05-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162779-A1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES BCAT1, BCAT2, ABAT ALDH1A1 812/4885KMT2A 646/4885RAB9A 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback